Sunday 18 October 2026
Export NAUT’s income statement to Excel — free account
Nautilus Biotechnology, Inc.
NAUT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 8.33% and free cash flow fell 3.16%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.06
0.10
−4.63%
Follow NAUT
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 10.06 | 4.41 | 1.50 | 1.57 | 1.61 | 0.62 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 11.84 | 25.89 | 5.34 | 4.65 | 3.25 | 2.54 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 3 | 113 | 134 | 167 | 155 | 130 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | — | — | (16) | (50) | (58) | (64) | (71) | (59) | |||||
| EBT margin, % | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | 0 | (16) | (50) | (58) | (64) | (71) | (59) | |||||
| Depreciation | — | — | — | — | 3 | 3 | 3 | 3 | 4 | 5 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | (0.54) | (0.60) | (0.46) | (0.51) | (0.56) | (0.47) | |||||
| Cash flow | — | — | — | — | (0.48) | (0.46) | (0.37) | (0.41) | (0.47) | (0.40) | |||||
| Capex | — | — | — | — | (0.03) | (0.03) | (0.02) | (0.02) | (0.02) | (0.01) | |||||
| Free cash flow | — | — | — | — | (0.51) | (0.49) | (0.39) | (0.43) | (0.49) | (0.41) | |||||
| Book value | — | — | — | — | (1.02) | 4.30 | 2.53 | 2.12 | 1.66 | 1.24 | |||||
| Shares, m | — | — | — | — | 29 | 84 | 125 | 125 | 125 | 126 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | (14) | (39) | (46) | (52) | (59) | (51) | ||||
| Capex | — | — | — | — | (1) | (2) | (2) | (2) | (2) | (1) | |||||
| Free cash flow | — | — | — | — | (15) | (42) | (48) | (54) | (61) | (52) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | 75 | 343 | 180 | 168 | 125 | 98 | ||||
| Total debt | — | — | — | — | 113 | 30 | 30 | — | — | — | |||||
| Net debt | — | — | — | — | (77) | (346) | (184) | (173) | (130) | (103) | |||||
| Shareholders’ equity | — | — | — | — | (30) | 364 | 315 | 265 | 209 | 157 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (36.75) | (20.81) | (15.48) | (19.42) | (25.82) | (27.20) | ||||
| ROIC | — | — | — | — | 0.00 | (176.84) | (30.48) | (51.77) | (64.59) | (77.98) | |||||
| ROE | — | — | — | — | (9.36) | (30.14) | (17.07) | (21.95) | (29.86) | (32.27) | |||||
Negative figures in brackets.
Latest quarter Jun 2026
Charts ten years each
Nautilus Biotechnology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| FULC Fulcrum Therapeutics, Inc. | $280.0M | — (loss-making) | — (loss-making) | +27,018.64% (above 0%: growing) | n/m | −13.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| OCGN Ocugen, Inc. | $275.9M | — (loss-making) | — (loss-making) | +8.38% (above 0%: growing) | n/m | −13.42% (below 0%: shrinking) | 100.00% | (1,105.11%) | Compare |
| NAUT Nautilus Biotechnology, Inc. | $274.9M | — (loss-making) | — | — | n/m | −3.16% (below 0%: shrinking) | 92.11% | (8,296.32%) | |
| IPSC Century Therapeutics, Inc. | $271.6M | — (loss-making) | — (loss-making) | +12,667.72% (above 0%: growing) | n/m | +26.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EYPT EyePoint, Inc. | $270.7M | — (loss-making) | — (loss-making) | −90.49% (below 0%: shrinking) | n/m | +0.41% (above 0%: growing) | 100.00% | (19,207.10%) | Compare |
| PALI Palisade Bio, Inc. | $268.4M | 2.2× | — (loss-making) | +19,900.00% (above 0%: growing) | n/m | −318.44% (below 0%: shrinking) | 100.00% | (2,339.60%) | Compare |
| ABEO Abeona Therapeutics Inc. | $265.9M | — (loss-making) | — (loss-making) | +225.14% (above 0%: growing) | n/m | +17.11% (above 0%: growing) | 63.30% | (119.97%) | Compare |
| PRLD Prelude Therapeutics Incorporated | $265.0M | — (loss-making) | — (loss-making) | +42.60% (above 0%: growing) | n/m | +40.32% (above 0%: growing) | 100.00% | (270.93%) | Compare |
| CABA Cabaletta Bio, Inc. | $262.8M | — (loss-making) | — | — | n/m | −35.72% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $269.5M | — | — | +225.14% | — | −6.32% | 100.00% | (195.45%) |
Nautilus Biotechnology, Inc. (NAUT) key facts
- Nautilus Biotechnology, Inc. (NAUT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, NAUT traded at $2.06, a market capitalization of $274.9 million.
- Return on equity was −32.3% and debt-to-equity 0.00.